Compare EPAM Systems Inc (EPAM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs TransMedics Group Inc — how do they compare? EPAM Systems Inc trades at $99.88 (market cap $5.15B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: EPAM Systems Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, EPAM Systems Inc nearer its low. Which is the better fit depends on your goals.
| EPAM | TMDX | |
|---|---|---|
Market Cap | $5.15B | $3.10B |
Sector | Technology | Technology |
52-Week High | $221.40 | $150.42 |
52-Week Low | $76.04 | $61.99 |
Enterprise Value | $4.52B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $100.29, up 3.0% with recent earnings beats but faces technical bearish signals. The company reported strong Q2 2026 results with EPS of $3.38 beating estimates, though revenue guidance was lowered due to North American softness. Valuation appears attractive with P/E of 13.55 and P/S of 0.97, while profitability metrics remain solid with 7.15% net margin.
The stock presents a value opportunity with analyst consensus target of $117.27 (17% upside), but faces near-term headwinds from reduced revenue guidance and technical weakness. Key risks include slowing demand in core markets, while the OpenAI partnership offers AI growth potential. Institutional sentiment remains positive with 65% buy ratings.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
